睿知中国医院研究地图
候选清单

正在招募多发性骨髓瘤I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验。牵头方不是本站收录的医院;本站收录的 4 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 4

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面
  2. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  3. 研究中心西安交通大学第二附属医院Second Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  4. 研究中心浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07454187,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Resolution of adverse events related to prior antineoplastic therapy to Grade ≤ 1 or baseline (CTCAE v6.0).

    入选标准第 7 条

  3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.

    入选标准第 2 条

  4. Any other malignancy diagnosed within 5 years prior to the first dose.

    排除标准第 25 条

  5. Female participants of childbearing potential and male participants whose partners are of childbearing potential must use at least one acceptable method of contraception during study treatment and for at least 7 months after the last dose.

    入选标准第 8 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07454187,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥ 18 years and ≤ 80 years.
  2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  3. Life expectancy ≥ 3 months.
  4. Documented diagnosis of multiple myeloma.
  5. Measurable disease at screening (per IMWG criteria).
  6. Relevant laboratory values obtained within 7 days prior to the first dose must meet protocol-specified thresholds.
  7. Resolution of adverse events related to prior antineoplastic therapy to Grade ≤ 1 or baseline (CTCAE v6.0).
  8. Female participants of childbearing potential and male participants whose partners are of childbearing potential must use at least one acceptable method of contraception during study treatment and for at least 7 months after the last dose.
  9. Male participants must refrain from sperm donation from the signing of the Informed Consent Form (ICF) until at least 7 months after the last study dose.

排除标准:Exclusion Criteria:

  1. Patients with primary refractory multiple myeloma.
  2. Presence of non-bone-related extramedullary soft tissue plasmacytoma at screening.
  3. known meningeal or Central Nervous System involvement of multiple myeloma, or high suspicion of unconfirmed meningeal or Central Nervous System involvement.
  4. History of peripheral neuropathy of Grade ≥ 2.
  5. Active infection requiring systemic therapy within 2 weeks prior to the first dose.
  6. Hypertension that was not effectively controlled by standardized antihypertensive treatment within 2 weeks prior to the first dose, as judged by the investigator
  7. History of hypertensive crisis or hypertensive encephalopathy.
  8. Poorly controlled diabetes mellitus.
  9. Severe cardiovascular or cerebrovascular disease within 6 months prior to the first dose.
  10. Active hepatitis B or hepatitis C infection.
  11. Known history of active tuberculosis or active syphilis.
  12. Known hypersensitivity to any component of the investigational product.
  13. history of Grade 3-4 allergic reaction or life threatening hypersensitivity to any biological product.
  14. Received any of the following therapies or surgeries.
  15. Prior treatment with LILRB4 targeted therapy; or severe adverse reaction to prior MMAE containing therapy.
  16. Immunotherapy, macromolecular targeted therapy, or other antineoplastic biologic therapy within 28 days prior to the first dose.
  17. Cytotoxic chemotherapy or small molecule therapy within 14 days prior to the first dose.
  18. Modernized traditional Chinese herbal medicine with approved antineoplastic indications within 7 days prior to the first dose.
  19. Requirement for systemic corticosteroids (equivalent to > 10 mg prednisone per day) or other immunosuppressive agents within 14 days prior to the first dose or during the study.
  20. Administration of any live or live attenuated vaccine within 28 days prior to the first dose.
  21. Administration of other vaccines (e.g., inactivated COVID-19 vaccine) within 14 days prior to the first dose.
  22. Immune related toxicity during prior antineoplastic immunotherapy that resulted in permanent treatment discontinuation.
  23. Current or previous idiopathic pulmonary fibrosis or idiopathic pneumonia;
  24. Current acute pulmonary disease, interstitial lung disease, or pneumonia.
  25. Any other malignancy diagnosed within 5 years prior to the first dose.
  26. Documented history of neurological or psychiatric disorder.
  27. Any other condition that, in the opinion of the investigator, may render the participant unsuitable for study participation.

引自 ClinicalTrials.gov, NCT07454187, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07454187,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07454187